Anna Turetsky, Ph.D.
Vice President

Anna is a Vice President at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Boston office.

Before joining Lightstone, Anna was an Analyst at Fletcher Spaght Inc., a healthcare strategy consulting firm in Boston. While at Fletcher Spaght, she advised clients in the medical device, biopharmaceutical, and healthcare IT sectors. Anna’s projects included researching and presenting market growth stories for public M&A transactions, supporting private equity due diligence for device deals, and developing best practices and strategy for a first-time life science venture fund in Canada.

Anna holds a PhD from Harvard University, which she completed under the guidance of Professor Ralph Weissleder, Director of the Center for Systems Biology at Massachusetts General Hospital. Her interdisciplinary research combined chemical biology, engineering, and translational medicine to develop novel cancer diagnostics. While at Harvard, Anna was a National Science Foundation Graduate Research Fellow, an Early Technology Assessment Fellow at the Harvard Office of Technology Development, and held leadership positions in several career development-focused student groups. She also completed life science and corporate finance coursework at MIT Sloan School of Management and Harvard Business School. Anna’s additional work experience includes an internship with Siemens Venture Capital and consulting for Innotrove, LLC, an advisor to Merck’s MRL Ventures.


Ph.D. in Biophysics from Harvard University
B.A. in Biochemistry from the University of Pennsylvania